Injectable / Longevity, Cognitive & Immunity

FOXO4-DRI

Senolytic Peptide · 10mg

FOXO4-DRI, injectable, front

$179 USD per unit · Coming soon · 10mg / 2mL vial

Cell-penetrating senolytic peptide that disrupts the FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells while sparing healthy tissue.

Product information

FOXO4-DRI is a first-in-class senolytic peptide designed to selectively eliminate senescent cells, aged cells that have stopped dividing but remain metabolically active, secreting pro-inflammatory factors (the SASP). The peptide works by disrupting the interaction between FOXO4 and p53, two proteins that cooperate to protect senescent cells from apoptosis. By breaking this protective interaction, FOXO4-DRI restores p53's pro-apoptotic function specifically in senescent cells, triggering their selective removal.

Senescent cell accumulation is a hallmark of biological aging, contributing to tissue dysfunction, chronic inflammation, and age-related disease. FOXO4-DRI represents a targeted approach to cellular rejuvenation, clearing senescent cells without affecting healthy dividing cells. Research demonstrates restoration of tissue function and reversal of aging phenotypes in preclinical models. This is cellular housekeeping at the molecular level.

Benefits

  • Selective senescent cell clearance
  • FOXO4-p53 interaction disruption
  • Anti-inflammatory SASP reduction
  • Tissue rejuvenation support
  • Healthy cell preservation
  • Cellular aging reversal mechanism

Specifications

Fill / pack
10mg / 2mL vial
Format
Injectable
Serving
5mg / dose
Servings per container
2 doses
Listed purity
99.3%
Molecular weight / composition
~3000 Da (modified peptide)
Storage
Refrigerate 2-8°C

For laboratory and research use only. Not for human consumption.